title: Chronic acetazolamide monotherapy in the treatment of juvenile myoclonic epilepsy.
abstract: We reviewed the charts of 84 patients with juvenile myoclonic epilepsy (JME) whom we had followed over the past 12 years, and identified 51 treated with acetazolamide (AZM) either because of a poor response to conventional antiepileptic drugs or to avoid valproate-associated adverse effects. Among the 51 we could isolate the effect of AZM on the generalized tonic-clonic seizures (GTCS) of JME in thirty-one. Chronic AZM monotherapy controlled GTCS in 14 of 31 patients. Most tolerated AZM very well; 5, however, developed renal calculi. Chronic AZM monotherapy controls GTCS in some patients with JME, but the development of renal calculi may limit its usefulness.
authors.affiliation: Department of Neurology, Columbia University College of Physicians and Surgeons, New York, NY.
authors.forename: S R
authors.initials: SR
authors.lastname: Resor
authors.forename: L D
authors.initials: LD
authors.lastname: Resor
mesh_terms: D000086:Acetazolamide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D000927:Anticonvulsants / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D004341:Drug Evaluation; D004831:Epilepsies, Myoclonic / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007669:Kidney Calculi / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D013997:Time Factors
chemical_list: D000927:Anticonvulsants; D000086:Acetazolamide